Fujifilm India Installs 125 AMULET Innovality Digital Mammography Machines Across India

New Delhi : FUJIFILM India, a leading pioneer in advancing healthcare imaging technologies, has achieved a significant milestone by deploying 125 AMULET Innovality digital mammography machines across India, marking a noteworthy advancement in the field of digital mammography. This achievement underscores the company’s commitment to enhancing the fight against breast cancer and expanding its installation base continually.

According to Globocan data from 2020, breast cancer constituted 13.5% (178,361 cases) of all cancer diagnoses and 10.6% (90,408 cases) of all cancer-related deaths in India. These statistics emphasize the critical importance of early breast cancer detection in improving survival rates.

As reported by IndiaEducationDiary.com, FUJIFILM India believes it has a societal obligation to raise awareness about early breast cancer detection and equip healthcare professionals with cutting-edge technologies to better serve the community. To further this mission, the ‘Together Against Breast Cancer’ conference was held in Goa from September 15th to 17th, 2023.

Koji Wada, Managing Director, FUJIFILM India said, “At FUJIFILM India, our unwavering commitment to women’s health is exemplified by the technologies we bring and the advocacy we do for early diagnosis. The installation of 125 AMULET Innovality digital mammography machines across India are a testament to our dedication to enhance healthcare infrastructure for the early detection of breast cancer. However, I strongly feel that 125 is just a milestone in this journey and we will be expanding our installation base with a very fast pace in the near future. Beyond our advancements in healthcare technology, our ‘Together Against Breast Cancer’ Conference is proudly celebrating its 3rd edition, reinforcing our commitment to raising awareness. We firmly believe that improving access to technology and increasing awareness are pivotal steps toward fostering a healthier India”.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre